In a major push to address the high cost of medicines and boost local pharmaceutical manufacturing, the Federal Government has launched MediPool, a new strategic procurement platform aimed at revolutionizing Nigeria’s healthcare supply chain.
Unveiled on Monday, June 2, by the Coordinating Minister of Health and Social Welfare, Prof. Muhammad Pate, the initiative was shared in a video statement via his official X handle.
Pate described MediPool as a Group Purchasing Organisation designed to improve efficiency, reduce medication prices, and catalyze domestic production through aggregated public sector demand and smart procurement.
“With the approval of MediPool, President Bola Tinubu has once again demonstrated clear, courageous leadership in confronting the longstanding challenges of affordability and access,” Pate said. “This initiative brings renewed hope to millions of Nigerians burdened by illness and the high cost of care.”
MediPool will begin operations by serving healthcare facilities under the Basic Healthcare Provision Fund, which currently supports services for over 37 million Nigerians. The programme is expected to expand in future phases to include federal tertiary hospitals and private healthcare providers, making it a nationwide solution.
Operating under a Public-Private Partnership model, MediPool will harness the government’s monopsony power — its ability to act as the primary buyer in a market — to negotiate better deals with suppliers, cut costs, and ensure quality and availability.
Pate noted that MediPool is a core pillar of the broader Presidential Initiative to Unlock the Healthcare Value Chain, which seeks to increase Nigeria’s self-sufficiency in pharmaceutical production.
READ ALSO: Tracking infrastructure development through PPP under Tinubu’s administration
The goal, according to Pate, is to manufacture 70% of all pharmaceuticals consumed locally and expand the life sciences workforce from 20,000 to 50,000 full-time jobs.
The minister also credited earlier reforms for paving the way, such as President Tinubu’s June 2024 Executive Order, which eliminated import duties on pharmaceutical raw materials. The policy has already started attracting international investment.
The European Investment Bank has flagged Nigeria as a key hub for pharmaceutical manufacturing, while the African Export-Import Bank has committed $1 billion to support the domestic production of medicines, biologics, and medical devices.
Highlighting on-ground progress, Pate mentioned significant milestones like the launch of Codex Bio Limited’s Rapid Diagnostic Test Kit Complex in Ogun State — the first WHO-approved partner in Africa for test kit production.
The plant will produce 147 million kits annually for diseases like HIV, malaria, and hepatitis. He also cited Jawa Investments Limited’s new beta-lactam facility in Lagos, which will scale production of essential antibiotics such as amoxicillin and clavulanic acid.
“These developments mark major steps toward achieving medicine security and affordability in Nigeria,” Pate said, adding that for a sustainable ecosystem, supply must be matched with predictable demand — a gap MediPool intends to fill.
If effectively executed and well-regulated, the MediPool platform could serve as a model for other African nations aiming to achieve medicine independence and ensure healthcare resilience.
“Rooted in smart policy, innovation, investment, and strong partnerships, MediPool is central to our broader goal of building an accessible, affordable, and sustainable healthcare system,” Pate concluded.
NAN
